Fig. 3From: Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trialClinical cure at the test-of-cure visit in ceftolozane/tazobactam- or meropenem-treated patients by renal function. ARC augmented renal clearance, CE clinically evaluable, ITT intention-to-treatBack to article page